Analysis of the therapeutic Effect of Huangkui Capsules combined with valsartan on Glomerulonephritis
Objective To explore the clinical efficacy of Huangkui capsule combined with valsartan in the treatment of glomerulonephritis(GN).Methods A total of 94 GN patients admitted to Shangqiu Traditional Chinese Medicine Hospital from June 2020 to February 2022 were selected.They were randomly divided into study group(n=47)and control group(n=47)using a random number table method.The control group was treated with valsartan,while the study group was treated with a combination of Huangkui capsules and valsartan.The clinical efficacy,24-hour urine protein levels,serum cytokine levels,and adverse reactions of the two groups were compared.Results The effective rate of treatment in the study group(93.62%)was higher than that in the control group(74.47%),and the difference was statistically significant(P＜0.05);The 24-hour urinary albumin excretion rate(AER)and 24-hour urinary protein level decreased in both groups after treatment,and the difference was statistically significant(P＜0.05).The study group was lower than the control group,and the difference was statistically significant(P＜0.05);After treatment,the levels of serum C-reactive protein(CRP),transforming growth factor-β1(TGF-β1),blood urea nitrogen(BUN)and serum creatinine(Scr)in the two groups were significantly lower than those in the control group,the difference was significant(P＜0.05),and the study group was lower than the control group,with statistical significance(P＜0.05);The incidence of adverse reactions in the study group(6.38%)was lower than that in the control group(21.28%),and the difference was statistically significant(P＜0.05).Conclusion The combination of Huangkui capsules and valsartan can improve treatment efficiency,improve protein and serum cytokine levels,and reduce adverse reactions in GN patients.
国家科技期刊平台
NSTL
万方数据
